BioCentury
ARTICLE | Company News

Ironwood ends gout drug deal with AZ

August 10, 2018 4:28 PM UTC

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) terminated its deal with AstraZeneca plc (LSE:AZN; NYSE:AZN) for rights to the pharma's gout drugs Zurampic lesinurad and Duzallo lesinurad/allopurinol.

Ironwood said franchise test markets of the drugs did not meet expectations. The biotech recorded $1.1 million in combined 2Q18 sales of Zurampic and Duzallo. Together the drugs generated sales of $3.1 million in 2017...